CoChat
Sign Up
Cited by 117Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsPharmacology and Obesity Treatment

7. Obesity Management for the Treatment of Type 2 Diabetes:Standards of Medical Care in Diabetes—2018

Open access
American Diabetes Association·2018·Diabetes Care
DOI 10.2337/dc18-s007
Open this paper in CoChat — free accountOpen PDF

Abstract

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc18-s007

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 55

  1. UK Prospective Diabetes Study 7. UK Prospec- tive Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metabolism 1990;39:905-912
  2. Goldstein DJ. Beneficial health effects of mod- est weight loss. Int J Obes Relat Metab Disord 1992;16:397-415
  3. Pastors JG, Warshaw H, Daly A, Franz M, Kulkarni K. The evidence for the effectiveness of medical nutrition therapy in diabetes manage- ment. Diabetes Care 2002;25:608-613
  4. Jackness C, Karmally W, Febres G, et al. Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and b-cell function in type 2 diabetic patients. Diabetes 2013;62:3027-3032
  5. Rothberg AE, McEwen LN, Kraftson AT, Fowler CE, Herman WH. Very-low-energy diet for type 2 diabetes: an underutilized therapy? J Diabetes Complications 2014;28:506-510
  6. Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009;5:749-757
  7. Expert Consultation WHO; WHO Expert Con- sultation. Appropriate body-mass index for Asian populations and its implications for policy and in- tervention strategies. Lancet 2004;363:157-163
  8. Baum A, Scarpa J, Bruzelius E, Tamler R, Basu S, Faghmous J. Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial. Lancet Diabetes Endocrinol 2017;5:808-815
  9. Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta- analysis of randomized clinical trials. J Acad Nutr Diet 2015;115:1447-1463
  10. Johnston BC, Kanters S, Bandayrel K, et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA 2014;312:923-933
  11. Raynor HA, Anderson AM, Miller GD, et al.; Look AHEAD Research Group. Partial meal re- placement plan and quality of the diet at 1 year: Action for Health in Diabetes (Look AHEAD) trial. J Acad Nutr Diet 2015;115:731-742
  12. Gudzune KA, Doshi RS, Mehta AK, et al. Effi- cacy of commercial weight-loss programs: an up- dated systematic review. Ann Intern Med 2015; 162:501-512
  13. Tsai AG, Wadden TA. The evolution of very- low-calorie diets: an update and meta-analysis. Obesity (Silver Spring) 2006;14:1283-1293
  14. Cai X, Yang W, Gao X, Zhou L, Han X, Ji L. Baseline body mass index and the efficacy of hy- poglycemic treatment in type 2 diabetes: a meta- analysis. PLoS One 2016;11:e0166625 29. Phentermine. FDA prescribing information, side effects and uses [Internet], 2017. Available from https://www.drugs.com/pro/phentermine .html. Accessed 22 September 2017
  15. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74-86
  16. Greenway FL, Fujioka K, Plodkowski RA, et al.; COR-I Study Group. Effect of naltrexone plus bu- propion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double- blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595-605
  17. Khera R, Murad MH, Chandar AK, et al. Asso- ciation of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016;315:2424- 2434
  18. O'Neil PM, Smith SR, Weissman NJ, et al. Ran- domized placebo-controlled clinical trial of lorca- serin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426-1436
  19. Rubino F, Nathan DM, Eckel RH, et al.; Dele- gates of the 2nd Diabetes Surgery Summit. Met- abolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 2016;39: 861-877
  20. Rubino F, Marescaux J. Effect of duodenal- jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004;239:1-11
  21. Sjöström L, Lindroos A-K, Peltonen M, et al.; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-2693
  22. Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term re- mission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014; 311:2297-2304
  23. Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA 2012;308:1122-1131
  24. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012;307:56-65
  25. Adams TD, Gress RE, Smith SC, et al. Long- term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-761
  26. Arterburn DE, Olsen MK, Smith VA, et al. As- sociation between bariatric surgery and long- term survival. JAMA 2015;313:62-70
  27. Adams TD, Arterburn DE, Nathan DM, Eckel RH. Clinical outcomes of metabolic surgery: mi- crovascular and macrovascular complications. Di- abetes Care 2016;39:912-923
  28. Rubino F, Kaplan LM, Schauer PR, Cummings DE; Diabetes Surgery Summit Delegates. The Di- abetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg 2010;251:399-405
  29. Cummings DE, Cohen RV. Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol 2014;2:175-181
  30. Zimmet P, Alberti KGMM, Rubino F, Dixon JB. IDF's view of bariatric surgery in type 2 diabetes. Lancet 2011;378:108-110
  31. Kasama K, Mui W, Lee WJ, et al. IFSO-APC consensus statements 2011. Obes Surg 2012;22: 677-684
  32. Ikramuddin S, Korner J, Lee W-J, et al. Dura- bility of addition of Roux-en-Y gastric bypass to lifestyle intervention and medical management in achieving primary treatment goals for uncon- trolled type 2 diabetes in mild to moderate obe- sity: a randomized control trial. Diabetes Care 2016;39:1510-1518
  33. Sjöholm K, Pajunen P, Jacobson P, et al. In- cidence and remission of type 2 diabetes in re- lation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study. Diabetologia 2015;58:1448-1453
  34. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and re- lapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013;23:93-102
  35. Schauer PR, Bhatt DL, Kirwan JP, et al.; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes: 5-year outcomes. N Engl J Med 2017;376:641-651
  36. Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care 2012;35:1420- 1428
  37. Brethauer SA, Aminian A, Romero-Talamás H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese pa- tients with type 2 diabetes mellitus [discussion appears in Ann Surg 2013;258:636-637]. Ann Surg 2013;258:628-636
  38. Hsu C-C, Almulaifi A, Chen J-C, et al. Effect of bariatric surgery vs medical treatment on type 2 diabetes in patients with body mass index lower than 35: five-year outcomes. JAMA Surg 2015; 150:1117-1124
  39. Schauer PR, Bhatt DL, Kirwan JP, et al.; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes: 3-year outcomes. N Engl J Med 2014;370:2002-2013
  40. Yu H, Di J, Bao Y, et al. Visceral fat area as a new predictor of short-term diabetes remission after Roux-en-Y gastric bypass surgery in Chinese patients with a body mass index less than 35 kg/m 2 . Surg Obes Relat Dis 2015;11:6-11
  41. Halperin F, Ding S-A, Simonson DC, et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg 2014; 149:716-726
  42. Courcoulas AP, Christian NJ, Belle SH, et al.; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA 2013;310: 2416-2425
  43. Arterburn DE, Courcoulas AP. Bariatric sur- gery for obesity and metabolic conditions in adults. BMJ 2014;349:g3961
  44. Young MT, Gebhart A, Phelan MJ, Nguyen NT. Use and outcomes of laparoscopic sleeve gastrec- tomy vs laparoscopic gastric bypass: analysis of the American College of Surgeons NSQIP. J Am Coll Surg 2015;220:880-885
  45. Aminian A, Brethauer SA, Kirwan JP, Kashyap SR, Burguera B, Schauer PR. How safe is metabolic/ diabetes surgery? Diabetes Obes Metab 2015;17: 198-201
  46. Birkmeyer NJO, Dimick JB, Share D, et al.; Michigan Bariatric Surgery Collaborative. Hospital complication rates with bariatric surgery in Mich- igan. JAMA 2010;304:435-442
  47. Altieri MS, Yang J, Telem DA, et al. Lap band outcomes from 19,221 patients across centers and over a decade within the state of New York. Surg Endosc 2016;30:1725-1732
  48. Hutter MM, Schirmer BD, Jones DB, et al. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effective- ness positioned between the band and the bypass [discussion appears in Ann Surg 2011;254:420- 422]. Ann Surg 2011;254:410-420
  49. Birkmeyer JD, Finks JF, O'Reilly A, et al.; Mich- igan Bariatric Surgery Collaborative. Surgical skill and complication rates after bariatric surgery. N Engl J Med 2013;369:1434-1442
  50. Rubin JK, Hinrichs-Krapels S, Hesketh R, Martin A, Herman WH, Rubino F. Identifying bar- riers to appropriate use of metabolic/bariatric sur- gery for type 2 diabetes treatment: policy lab results. Diabetes Care 2016;39:954-963
  51. Fouse T, Schauer P. The socioeconomic im- pact of morbid obesity and factors affecting access to obesity surgery. Surg Clin North Am 2016;96:669-679
  52. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyper- insulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353:249-254
  53. Lee CJ, Clark JM, Schweitzer M, et al. Preva- lence of and risk factors for hypoglycemic symp- toms after gastric bypass and sleeve gastrectomy. Obesity (Silver Spring) 2015;23:1079-1084
  54. Conason A, Teixeira J, Hsu C-H, Puma L, Knafo D, Geliebter A. Substance use following bariatric weight loss surgery. JAMA Surg 2013;148:145- 150
  55. Greenberg I, Sogg S, M Perna F. Behavioral and psychological care in weight loss surgery: best practice update. Obesity (Silver Spring) 2009;17: 880-884

Cited by

Sorted by citations

Authors
American Diabetes Association
Corresponding author
American Diabetes Association
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2017-11-24
Volume
41
Issue
Supplement_1
Pages
S65-S72
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/dc18-s007
OpenAlex
W4242664296
Cited by
117
References
22
Citations by year
2026: 3 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 10 · 2021: 10 · 2020: 17 · 2019: 36 · 2018: 24
FWCI
3.07
Type
journal article
Language
en
Open access
Licence
www.diabetesjournals.org/content/license (vor, 26 d)
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Keywords
obesity treatment, type 2 diabetes, diabetes management guidelines, clinical guidelines, quality of care
MeSH terms
Obesity Management, Diabetes Mellitus, Type 2, Diet Therapy, Exercise Therapy, Humans, Obesity, Cognitive Behavioral Therapy, Anti-Obesity Agents, Bariatric Surgery, Standard of Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review